Introduction
Acute lymphoblastic leukemia (ALL) is a clonal disorder of lymphoid progenitors with distinctive morphologic, immunophenotypic and genotypic features and represents the most frequent malignancy of childhood. 1 ALL affects T-or B-lineage precursor cells, the latter accounting for approximately 80% of the cases in Europe and the USA. Immunophenotype allows further subdivision of Blineage ALL into pro-B (CD19 þ , CD10 À ), common (CD19 þ , CD10 þ ), pre-B (CD19 þ , cytoplasmic immunoglobulin (Ig) þ ) and mature B (surface Ig þ ). However, with some exceptions, this classification bears scarce utility for survival prediction. 2 Several prognostic factors that herald poor outcome have been described in childhood ALL. Infants less than 1-year of age (infant leukemia) have a poor rate of survival. 1 MLL translocation is another adverse prognostic factor and the gene is rearranged in about 80% of infant leukemias. 3 Translocations involving E2A/PBX1 and BCR/ABL, present in approximately 8-10% of childhood ALL, are also predictors of poor outcome. 4 The rate of cure in children ALL is over 70%. It appears likely that the intensification of existing treatments will not improve the cure rate substantially but, rather, it might increase treatment-related mortality due to toxicity or to the onset of second cancers. 1 Thus, beyond a better understanding of the molecular mechanisms of disease and resistance to chemotherapy, the identification of markers potentially suitable for chemotherapy and/or immunotherapeutic approaches may be useful in cases that have poor outcome.
CD1d belongs to the monomorphic family of CD1 molecules involved in presentation of glycolipids to CD1-restricted T cells. 5 Among hematopoietic cells, CD1d is expressed on antigen-presenting cells, a proportion of B lymphocytes, monocytes and immature cortical thymocytes. 5 The finding that a-galactosylceramide (a-GalCer), a glycolipid molecule derived from a marine sponge, is able to be presented via CD1d to most CD1d-restricted T cells, 5 has boosted the functional characterization of these cells. In humans, most CD1d-restricted T cells show a limited T-cell receptor (TCR) repertoire consisting of TCR variable (V) alpha 24 chains paired with TCR V beta 11 chains. 5 In addition, natural killer (NK) cell markers, such as CD161, have been detected in a proportion of these cells. 6 Owing to these features, CD1d-restricted T cells are also termed invariant NKT cells. We will refer to these cells as NKT throughout the paper.
NKT cells have important regulatory functions in the immune system, mainly mediated by the secretion of both Th1 and Th2 cytokines. Involvement of CD1d-restricted T cells has been observed in autoimmune diseases and during infection with a variety of microbial pathogens (reviewed in Brigl and Brenner 5 ). In humans, B lymphocytes expressing CD1d are found in peripheral blood (PB) 5, 7 and in the mantle zone of secondary lymphoid follicles. 5 So far, no data are available on CD1d expression in B-cell precursors (BCPs).
Here we have studied the expression of CD1d in the leukemic blasts derived from a cohort of 80 children with BCP-ALL. CD1d was detected in ALL cells from a minority of patients (n ¼ 12, 15%). CD1d þ cases were significantly more represented in BCP-ALL subgroups known to have poor survival rate. Accordingly, CD1d þ ALL cases had significantly lower overall survival. CD1d expression was also observed in BM BCPs from normal donors. Functional studies allowed to determine that CD1d þ ALL cells loaded with a-GalCer underwent apoptosis induced by NKT cells and were able to elicit cytokine secretion by the latter cells. Thus, CD1d expressed on BCP-ALL cells mediates presentation of immunogenic lipid(s) to CD1d-restricted T cells.
These data may help to explore novel immunotherapeutic approaches in ALL cases that express CD1d and are expected to have poor outcome on conventional treatments.
Materials and methods

Patients and normal bone marrow (BM) donors
The study population included 80 children with ALL of BCP origin. ALL cases were part of a bank of cryo-preserved samples collected between January 1995 and July 2003. Samples were analyzed on the basis of the availability of frozen cells and, therefore, are not representative of a consecutive series of patients. Clinical data included age, sex, white blood cell count at diagnosis, assessment of hepatomegaly, splenomegaly, and BM and central nervous system (CNS) involvement. Informed consent was obtained from parents. Diagnosis and categorization resulted from morphologic analysis of BM aspirates, immunophenotyping, and cytogenetic and molecular genetic analysis of PB and/or BM samples. Immunophenotyping included analysis with a standard panel of monoclonal antibodies (mAb) to CD19, CD10, CD34, cytoplasmic and surface Ig. Cases were classified as pro-B ALL (n ¼ 12), common ALL (n ¼ 47), pre-B ALL (n ¼ 21). No mature B-ALL cases (sIg þ ) were observed in this series. Classification of ALL according to age allowed identification of six infant ALL (o1 year) and 74 noninfant ALL cases.
Samples from 60 patients were available for cytogenetic and molecular genetic studies. Cytogenetic analyses were performed on BM cells after 24 h of unstimulated culture. GTG bands with trypsin were obtained. Karyotypes were reviewed and defined according to the ISCN criteria. Molecular studies were carried out on RNA extracted from BM or PB cells using the multiplex RT-PCR assay, as described previously, 8 that is able to detect the following fusion transcripts: MLL/AF4, MLL/ENL, BCR/ABL, TEL/ AML1, E2A/PBX1, SIL/TAL1 and NUP98/RAP1GDS1. MLL/AF4 fusion transcripts were observed in 10 cases, TEL/AML1 in three cases, BCR/ABL in two cases and E2A/PBX1 in one case. A hyperdiploid karyotype (more than 50 chromosomes) was found in six cases and one patient had trisomy 21 (Down's syndrome). In total, 37/60 patients displayed a normal karyotype and the absence of molecular genetic abnormalities.
Patients were treated according to AIEOP (Italian Association of Pediatric Hematology and Oncology) protocols: ALL 91, ALL 95, ALL 2000 and Interfant 99. Patients and adverse events were proportionally distributed among the protocols, with the exception of the Interfants 99 protocol, which included infant leukemia patients only.
Seven normal BM samples were obtained, after parents informed consent, from children undergoing diagnostic laboratory procedures, which did not reveal hematological abnormalities. Cells derived from normal BM samples were isolated by density gradient separation on Ficoll-Paque (Amersham Biosciences, Milan, Italy).
Antibodies and immunostaining
For ALL and normal BM cell staining the following mAb were used: CD1d-phycoerythrin (PE), CD10-PE, CD10-fluorescein isothiocyanate (FITC), CD38-FITC, CD19-peridinin chlorophyll protein-cyanine dye 5.5. (PerCP-Cy5.5), CD34 FITC and fluorochrome-conjugated isotype-matched control mAbs (Becton Dickinson Italia, Milan, Italy). Goat F(ab)2 anti-human IgD-FITC was purchased from Caltag (Caltag Laboratories, Burlingame, CA, USA). Antibodies to CD1d and CD1c used for functional experiments are described below. Details of the staining procedure are reported in Fais et al. 
Isolation of NKT cell lines
The NKTA cell line has been described previously. 7 The NKTLE cell line was expanded from a healthy donor as detailed in Fais et al. 7 The NKTA line is comprised predominantly of CD4 À / CD8
À cells, has cytotoxic activity 7 and has been used to evaluate CD1d-restricted cytotoxicity of ALL cells. The NKTLE line is comprised predominantly of CD4 þ cells, and displays a wider and higher cytokine production in comparison with NKTA. Therefore, the NKTLE line has been used to evaluate NKT cytokine production following stimulation with ALL cells.
ALL cell purification
For the evaluation of cytotoxicity and cytokine production by NKT cells, ALL cells were negatively selected using a mixture of anti-CD3, -CD14, -CD56 coated microbeads (Miltenyi Biotec, Milan, Italy). Separation was performed on LD columns (Miltenyi Biotec). In all instances, leukemic cells were 98% pure.
Cytotoxic activity of NKT cells against ALL cells
The detailed procedure for the evaluation of cytotoxicity of NKT against ALL cells has been provided in the Supplementary information accompanying the paper.
Cytokine production by NKT cells
The detailed procedure for the evaluation of cytokine secretion of NKT cells following incubation with ALL cells has been provided in the Supplementary information accompanying the paper.
Statistical analyses
The two-tailed Fisher's exact test was used to determine whether subsets of ALL distinguished according to immunophenotype, karyotype, age and follow-up outcome were significantly associated with CD1d expression on ALL cells. The same test was used to evaluate the association of the combination of these subgroups and CD1d expression on ALL cells. Overall survival curves of CD1d þ and CD1d À BCP-ALL were estimated using the Kaplan-Meier method and the log-rank test was employed to evaluate statistical significance.
Results
CD1d expression on ALL cells
To determine CD1d expression on ALL cells, three-color flow cytometric analyses were performed on BM-or PB-derived mononuclear cells from patients with evidence of leukemic blast expansion and previously characterized as BCP-ALL. Expression of CD1d was evaluated on tumor cells identified as CD19 þ / HLA-DR þ . In total, 12 out of 80 cases (15%) showed expression of CD1d on leukemic cells. In nine cases all blasts were CD1d þ (figure provided as Supplementary material), whereas in three cases the expression of CD1d was detected on a proportion of leukemic blasts only (28, 66 and 20% respectively). Some degree of variation in the intensity of surface expression was
. In samples that showed monomodal expression of CD1d, the relative mean fluorescence intensity (RMFI) ranged from 3.02 to 24.72 (mean 9.1577.17).
Features of CD1d
þ ALL cases À ALL (P ¼ 0.002). In addition, a significant difference in the overall survival between CD1d þ and CD1d À ALL was observed (see Figure 1) . The estimated 5-year probability of overall survival was 44.4% (s.e. 15.5%) in CD1d þ ALL and 86.8% (s.e. 5.4%) in CD1d
À ALL (P ¼ 0.0001).
CD1d on ALL cells mediates a-GalCer presentation to NKT cell lines
To evaluate the ability of ALL cells to present a-GalCer to CD1d-restricted T cells, two NKT cell lines derived from normal donors were used and termed NKTA and NKTLE. In all instances, the NKT lines comprised 498% of TCR Va24 þ /Vb11 þ T cells 7 (and data not shown). Unlike NKTLE cells, the NKTA cell line is strongly cytotoxic, 7 and was therefore chosen to evaluate its ability to induce apoptosis of ALL cells, in the absence or in the presence a-GalCer.
Leukemic blasts derived from five cases of CD1d þ and two cases of CD1d À ALL were purified by negative selection. In all instances, ALL cells were 498% pure (not shown). CD1d þ ALL cases were selected on the basis of the availability of a sufficient number of cells and of the monomodal expression of CD1d. NKTA was unable to induce apoptosis of leukemic cells in all instances (Figure 2) , with the exception of one case in which a modest level of cell death was observed. Preincubation of ALL cells with a-GalCer significantly induced apoptosis of CD1d þ , but not of CD1d À blasts. Preincubation with the vehicle alone never yielded a significant apoptosis of leukemic cells. In addition, apoptosis was inhibited by addition of CD1d mAb, but not of the isotype-matched CD1c mAb.
Cytokine production by NKT cells in the presence of ALL cells and a-GalCer
Secretion of cytokines by NKT cells following incubation with CD1d
þ ALL cells and a-GalCer was evaluated using the cell line NKTLE and purified leukemic blasts derived from two patients. NKTLE was selected because, in preliminary experiments, this cell line produced higher amounts and wider range of cytokines in comparison with NKTA. Results are reported in Table 1 . Leukemic cells incubated with vehicle or with a-GalCer were used to stimulate NKTLE. Secretion of cytokines was evaluated using the CBA kit, which allows the cytometric evaluation of six cytokines (IL-2, IL-4, IL-5, IL-10, TNF-a and IFN-g). No secretion of cytokines was observed by NKTLE cells alone or after incubation with ALL cells and vehicle. Preincubation of ALL cells with a-GalCer resulted in the secretion of detectable amounts of IL-2, IL-5, TNF-a and g-IFN by cells from both cases. In one case, the stimulation of NKTLE cells was more efficient and low but detectable secretion of IL-4 was also observed. Cytokine production was inhibited in the presence of anti-CD1d, but not of anti-CD1c mAb.
Incubation of ALL cells from two CD1d À cases with NKTLE cells failed to induce the secretion of detectable amounts of cytokines in the presence of a-GalCer.
CD1d
þ BCPs are present in normal BM
To determine the expression of CD1d in normal BCPs, threecolor flow cytometric analyses were performed in BM cells derived from seven age-matched normal donors. CD19 þ / CD1d þ cells were found in 5/7 cases. In these five cases, CD19 þ /CD1d þ accounted for 2.6-45.0% of CD19 þ cells. In all instances, the majority of CD19 þ /CD1d þ cells coexpressed sIgD (67-93%, see Figure 3a ), indicating that they were mature B lymphocytes. However, CD19
þ /CD1d þ /CD34 þ cells were clearly identified in two cases (one example is reported in Figure 3a ). When analyzing CD34 þ /CD19 þ cells, CD1d was detected on 0-2% of the cells in this subpopulation (see Figure 3b ). As virtually all of the CD34
þ cells were observed in 6/7 cases (range 0.5-10% of CD34 þ cells). In two cases, a sizeable proportion of CD34 þ /CD1d þ cells were CD19 þ (one example is reported in Figure 3c ). These results indicate that CD1d is found on a very small proportion (2% or less) of early BCPs, data consistent with our findings on Blineage ALL cells. þ (on the left side) and two CD1d À (on the right side) ALL samples. In all instances, at least three separate experiments were performed Table 1 Cytokine production by NKTLE cells following incubation with purified CD1d + ALL cells and a-GalCer Presence of 100 ng/ml of a-GalCer in the culture derived from two independent experiments. e Presence of 10 mg/ml of MoAb in the culture.
Discussion
The expression of the monomorphic molecule CD1d was evaluated on leukemic cells derived from pediatric BCP-ALL cases that were characterized at onset for immuno-phenotype, cytogenetics, molecular genetics and age. Follow-up was available for all but one patient. CD1d was detected on blasts from 15% of the patients. However, CD1d þ ALL cases were not distributed randomly in our cohort. A significant association with pro-B immunophenotype, MLL rearrangement and infant leukemia was found for CD1d þ cases. MLL rearrangement represents a major adverse prognostic factor that is present in a large proportion of infant leukemias and in pro-B ALL.
9-11 MLL rearrangement and infant leukemia are independent factors of poor prognosis. MLL-rearrangement was found in 5/6 cases of infant leukemia and in 10/12 pro-B ALL. Thus, as also apparent from previous studies, 10, 12 infant leukemia, pro-B ALL and MLL-rearranged ALL are largely overlapping subsets. In our cohort, the death rate for disease relapse/progression within these three groups considered together was 61.5% (8/13) as opposed to 6.1% (4/66) of the remaining cases (Po0.0001). In the same subgroups, expression of CD1d was detected in 54.3% of the cases (7/13) as opposed to 7.5% (5/67) of the remaining cases (P ¼ 0.0003).
Statistical analysis indicates that CD1d expression in ALL blasts is an adverse prognostic factor. However, given the relatively small number of CD1d þ cases available, it cannot be clearly stated whether CD1d provides an independent prognostic marker or rather its expression is associated with ALL subgroups with poor prognosis. This issue may be clarified by analysis of a larger and consecutive series of ALL cases.
Presently, no data on the expression of CD1d in normal BCPs are available. Therefore, we investigated whether BCPs from normal BM express CD1d. To this end, seven normal BM samples were analyzed. CD19 þ /CD1d þ cells were found in 5/7 cases. However, the majority of these cells were mature IgD þ B cells, which must be considered as contaminating PB cells or BM mature B cells. Thus, it appears that expression of CD1d generally coincides with the latest stages of B-cell maturation. However, CD1d expression was also observed in CD34 þ cells (up to 10% of CD34 þ cells). In two of the BM samples, a sizeable proportion of CD34 þ /CD1d þ cells were CD19 þ (one case is shown in detail in Figure 3 ). CD19
À /CD1d þ cells belong to the myeloid lineage as they express CD33 (not shown). Thus, CD1d is detected on CD34 þ /CD19 þ cells, although at a very low frequency. In addition, these cells were not found consistently in all samples.
Next, we asked whether CD1d þ ALL cells are able to mediate presentation of glycolipid antigen(s) to CD1d-restricted T cells. To this end, we took advantage of the well-characterized ability of a-GalCer to be presented to NKT cells via CD1d. In addition, since CD1d is a monomorphic molecule, allogeneic NKT cells could be employed. NKT cell lines derived from normal subjects 7 were used to evaluate cytotoxicity and cytokine production following incubation with CD1d þ ALL cells and aGalCer. The results show that, in the presence of a-GalCer, the cytotoxic cell line NKTA was able to induce apoptosis of CD1d þ but not of CD1d À ALL cells. Apoptosis of ALL cells was not observed in the absence of a-GalCer.
The ability of CD1d þ ALL blasts to stimulate NKT cells was also evaluated by measuring their cytokine secretion in the presence of a-GalCer. Two CD1d þ cases were used to this end. In both cases, a significant production of IL-5, TNF-a and g-IFN was observed only in the presence of a-GalCer. Secretion of IL-2 was somewhat less evident and IL-4 was detected only after culture with one ALL case that generally elicited a better response. Thus, the data indicate that CD1d expressed on ALL mediates antigen presentation to CD1d-restricted T cells.
The observation that CD1d is expressed in BCP-ALL subsets with poor prognosis and that CD1d þ blasts are able to interact with NKT cells via CD1d, may be relevant to evaluate the use of NKT cells and a-GalCer for immunotherapy. Given the monomorphic nature of CD1d, the use of allogeneic NKT cells is conceivable. As NKT cells can be massively expanded in vitro, the preparation of engineered cell lines that allow expression of drug-inducible genes 13 to limit possible damages deriving from the systemic effects of cytokine release (ie TNF-a) can be envisaged. This tool would be of value for BCP-ALL because of the rapid course of the disease. However, its possible use in other hematological malignancies has to be noted as CD1d is espressed in B-cell chronic lymphocytic leukemia, 7 T-ALL 14 and myelo-monocytic leukemia. 15 Thus, the application of this treatment, possibly implemented with current therapies, would deal with a large series of patients. Importantly, application of a-GalCer to humans has already been tested without major side effects. 16, 17 In conclusion, the expression of CD1d in a proportion of high risk BCP-ALL cases with low probability of long-term survival with conventional therapies and their ability to present lipid antigen(s) to CD1d-restricted T cells may provide new reagents potentially suitable for immunotherapeutic approaches.
